United Therapeutics (UTHR) Share-based Compensation (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Share-based Compensation data on file, last reported at $58.3 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 281.05% year-over-year to $58.3 million; the trailing twelve-month figure through Mar 2026 stood at $59.6 million (up 270.19% YoY), and the FY2025 full-year result was $16.6 million, up 36.07% from the prior year.
• Share-based Compensation grew to $58.3 million in Q1 2026, from -$92.1 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $105.5 million in Q3 2024 to a low of -$104.8 million in Q4 2024.
• A 5-year average of $6.6 million and a median of $11.4 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 15400.0% in 2022 and soared 400.0% in 2024, its largest moves.
• Tracing UTHR's Share-based Compensation over 5 years: stood at -$30.6 million in 2022, then surged by 71.57% to -$8.7 million in 2023, then plunged by 1104.6% to -$104.8 million in 2024, then climbed by 12.12% to -$92.1 million in 2025, then surged by 163.3% to $58.3 million in 2026.
• Business Quant data shows UTHR's Share-based Compensation at $58.3 million in Q1 2026, -$92.1 million in Q4 2025, and $93.2 million in Q3 2025.